Charles River Laboratories International Inc. (CRL) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Per the Roarable RQD rating, CRL scores 63 out of 100, a letter grade of C, with the verdict "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are: Fundamental Cash Engine at 13/20 (ROIC 0.4%; FCF yield 3.1%), Whale 13F Flow at 18/20 (institutional accumulation and options positioning), Insider Conviction at 10/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 10/20 (Beta 1.15; sector sensitivity), and Forensic Balance Sheet at 12/20 (Altman Z 3.65; Piotroski F 6/9; Debt/Equity 0.52).

The strongest pillar is institutional flow, which is the main upside driver in this rating. The weakest pillars are insider conviction and macro regime fit, which indicate limited insider-level confirmation and above-market sensitivity to broad moves (Beta 1.15). The fundamental pillar is modest, reflecting a 0.4% ROIC against a 3.1% FCF yield, so valuation support rests more on cash generation than on returns on invested capital. A prospective investor should weigh the strong flow signal against a valuation that the source data shows at a forward P/E of 23 and an EV/EBITDA of 95, a combination that leaves limited margin for error if cash generation or sentiment weakens.

Per the SEC financials, revenue was broadly flat across the three reported years while operating income declined from $617.3M in FY 2023 to $25.2M in FY 2025, and FY 2025 net income was negative at $-144.3M. Market data shows an operating margin of 0.6% and a net margin of -3.6%, with ROIC at 0.4%. Per the Roarable RQD rating, the Altman Z-Score is 3.65 and the Piotroski F-Score is 6/9, and Debt/Equity is 0.52. Free cash flow remained positive at $557.0M in FY 2025, and reported debt declined from $2310.8M in FY 2023 to $1765.9M in FY 2025.

The news feed contains six items, all tagged to CRL, and none includes substantive narrative beyond headlines and summaries. Items are labeled as market wire, catalyst, or market-wire items by impact classification. The headlines reference a strong trading day and outperformance versus competitors, a 12-month price target raised to $324.87 implying 8% upside, a GuruFocus GF Score of 64/100 with an overvalued GF Value designation, and a Simply Wall St piece on holder returns. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are recorded, so no proprietary signal analysis is available. Risk watch items based on the feed are the conflict between the raised price target and the GuruFocus overvaluation label, and the gap between the 52-week high of $379.63 and the current price of $376.1.

• What drove the decline in operating income from $617.3M in FY 2023 to $25.2M in FY 2025, and is the trend continuing?
• What is the trailing P/E, given that the source data reports EPS (TTM) of -3.02 but no P/E (TTM)?
• What products, customers, and revenue segments generate CRL's $4015.4M in FY 2025 revenue?
• What is the identity and size of the institutional holders underlying the 13F flow pillar score?
• What is the basis for the $324.87 price target, and what analyst consensus underlies it?